Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report.

Pasello G, Altavilla G, Bonanno L, Rea F, Favaretto AG.

J Thorac Dis. 2010 Dec;2(4):254. doi: 10.3978/j.issn.2072-1439.2010.02.04.2.

2.

Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.

Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS, Rimner A, Flores R, Rusch V.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1278-83. doi: 10.1016/j.ijrobp.2011.09.027. Epub 2012 May 18.

3.

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.

J Clin Oncol. 2006 Mar 20;24(9):1443-8.

PMID:
16549838
4.

A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.

Shimokawa M, Hasegawa S, Fukuoka K, Okada M, Yokoi K, Tanaka F, Yamanaka T, Daimon T, Nakano T.

Jpn J Clin Oncol. 2013 May;43(5):575-8. doi: 10.1093/jjco/hyt035. Epub 2013 Mar 17.

PMID:
23509402
5.

Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.

Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A.

Lung Cancer. 2011 Sep;73(3):351-5. doi: 10.1016/j.lungcan.2011.01.005. Epub 2011 Feb 5.

PMID:
21296448
6.

Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?

Li L, Razak AR, Hughes A.

Lung Cancer. 2009 May;64(2):207-10. doi: 10.1016/j.lungcan.2008.08.016. Epub 2008 Oct 15.

PMID:
18926592
7.

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.

J Thorac Oncol. 2008 Jul;3(7):756-63. doi: 10.1097/JTO.0b013e31817c73d6.

8.

[Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].

Chen WH, Zhang XL, Dai HP, Tong ZH, Zhang YH, Jin ML.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Nov;36(11):825-8. Chinese.

PMID:
24507393
9.

Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.

Green J, Dundar Y, Dodd S, Dickson R, Walley T.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005574. Review.

PMID:
17253564
10.

Patterns of failure following surgical resection for malignant pleural mesothelioma.

Jänne PA, Baldini EH.

Thorac Surg Clin. 2004 Nov;14(4):567-73. Review.

PMID:
15559064
11.

Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.

Sørensen JB, Sundstrøm S, Perell K, Thielsen AK.

J Thorac Oncol. 2007 Feb;2(2):147-52.

12.

Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.

Minatel E, Trovo M, Bearz A, Di Maso M, Baresic T, Drigo A, Barresi L, Furlan C, Del Conte A, Bruschi G, Fontana P, Pagan V, Franchin G.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):606-13. doi: 10.1016/j.ijrobp.2015.06.029. Epub 2015 Jun 20.

PMID:
26281826
13.

Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report.

Chung SM, Choi SJ, Kim MJ, Choi JY, Kim HJ, Lee SY, Kang EJ.

Oncol Lett. 2016 Jul;12(1):213-216. Epub 2016 May 17.

14.

Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.

Agatsuma T, Koizumi T, Yasuo M, Urushihata K, Tsushima K, Yamamoto H, Hanaoka M, Fukushima M, Honda T, Kubo K.

Jpn J Clin Oncol. 2010 Dec;40(12):1180-3. doi: 10.1093/jjco/hyq101. Epub 2010 Jul 4.

PMID:
20603247
15.

Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.

Kanai O, Fujita K, Nakatani K, Mio T.

Respirol Case Rep. 2016 Jan 14;4(1):28-31. doi: 10.1002/rcr2.145. eCollection 2016 Mar.

16.

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W.

Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2.

PMID:
26538423
17.

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.

Federico R, Adolfo F, Giuseppe M, Lorenzo S, Martino DT, Anna C, Adriano P, Gino C, Francesca R, Matteo C, Gbenga K, Paolo M, Francesco F.

BMC Cancer. 2013 Jan 16;13:22. doi: 10.1186/1471-2407-13-22.

18.
19.

Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.

Lang-Lazdunski L, Bille A, Papa S, Marshall S, Lal R, Galeone C, Landau D, Steele J, Spicer J.

J Thorac Cardiovasc Surg. 2015 Feb;149(2):558-65; discussion 565-6. doi: 10.1016/j.jtcvs.2014.10.041. Epub 2014 Oct 14.

20.

A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.

Rusch V, Saltz L, Venkatraman E, Ginsberg R, McCormack P, Burt M, Markman M, Kelsen D.

J Clin Oncol. 1994 Jun;12(6):1156-63.

PMID:
8201377

Supplemental Content

Support Center